Sling Therapeutics Announces $123 Million Series C Financing to Advance Phase 3 Development of its Oral Small Molecule IGF-1R Inhibitor for Thyroid Eye Disease

ANN ARBOR, Mich.--(BUSINESS WIRE)--Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the close of a $123 million Series C financing. The financing was led by Forbion and included participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management. Proceeds from the financing will support the continued clinical advancemen